Narayana I. Narasimhan

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah et al. · New England Journal of Medicine · 2012 · 770 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 404 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi et al. · Journal of Medicinal Chemistry · 2010 · 362 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Scott Gettinger, Lyudmila Bazhenova, Corey J. Langer et al. · The Lancet Oncology · 2016 · 350 citations

Medicine, Oncology, Pharmacology +14

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 326 citations · Full text

Medicine, Oncology, Pharmacology +15